Great Debate: Should Surgery Be Omitted in the Management of Gastroesophageal Junction Cancers?
Meredith A Gunder, Brian D Badgwell, Kaitlyn J Kelly · 2026
Read Great Debate: Should Surgery Be Omitted in the Management of Gastroesophageal Junction Cancers? by Meredith A Gunder, Brian D Badgwell, Kaitlyn J Kelly (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13585956.txt.
Description
Meredith A Gunder, Brian D Badgwell, and Kaitlyn J Kelly lay out a structured debate on skipping surgery for cancers at the join of stomach and food pipe. Drug treatment before surgery has grown so strong that some tumors vanish entirely by the time of the operation, which raises a hard question: who still needs a risky operation at all? Their 2026 article gives two expert camps their say.
The case for skipping rests on response rates: tumors with a certain repair defect cleared fully in about six of ten patients after immune therapy alone. The other camp notes that judging a full clear-out from scans and samples is unreliable, and that long-term proof is missing. The authors land on a split answer: skipping is worth weighing for that repair-defect group, while surgery stays standard for the rest.
Catalog record
| CREATOR | Meredith A Gunder, Brian D Badgwell, Kaitlyn J Kelly |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |